Class III β-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy

Cancer Research

Volumn 70, Issue 22, 2010, Pages 9253-9264

  Ploussard, Guillaume ^a,b,c   Terry, Stéphane ^a,b,d,e   Maillé, Pascale ^c   Allory, Yves ^a,b,c   Sirab, Nanor ^a,b   Kheuang, Laurence ^a   Soyeux, Pascale ^a   Nicolaiew, Nathalie ^a,b   Coppolani, Estelle ^a   Paule, Bernard ^c   Salomon, Laurent ^a,b,c   Culine, Stéphane ^a,b,c   Buttyan, Ralph ^f   Vacherot, Francis ^a,b   De La Taille, Alexandre ^a,b,c  

^a INSERM   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; BIOLOGICAL MARKER; DOCETAXEL; PREDNISONE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CASTRATION RESISTANT PROTATE CANCER; CELL STRAIN LNCAP; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; EXPRESSION VECTOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RETROSPECTIVE STUDY; RNA INTERFERENCE; TREATMENT RESPONSE; TUMOR CELL;

AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; ORCHIECTOMY; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SURVIVAL ANALYSIS; TAXOIDS; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 78549257475     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1447     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973-8.
3. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009;15:3251-5.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
6. Bamias A, Bozas G, Antoniou N, et al. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol 2008;53:323-31.
7. Yoshino T, Shiina H, Urakami S, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006;12:6116-24.
8. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70.
9. Lu Q, Luduena RF. Removal of β III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 1993;18:173-82.
10. Panda D, Miller HP, Banerjee A, Luduena RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A 1994;91:11358-62.
11. Sabbatini P, Spriggs DR. Epothilones: better or more of the same? J Clin Oncol 2009;27:3079-81.
12. Seve P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-75.
13. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9.
14. Galmarini CM, Treilleux I, Cardoso F, et al. Class III β-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 2008;14:4511-6.
15. Seve P, Reiman T, Isaac S, et al. Protein abundance of class III β-tubulin but not Δ2-α-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 2008;28:1161-7.
16. Seve P, Mackey J, Isaac S, et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with nonsmall cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
17. Urano N, Fujiwara Y, Doki Y, et al. Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006;28:375-81.
18. Seve P, Lai R, Ding K, et al. Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable nonsmall cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007;13:994-9.
19. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998;77:562-6.
20. Ranganathan S, McCauley RA, Dexter DW, Hudes GR. Modulation of endogenous β-tubulin isotype expression as a result of human β(III) cDNA transfection into prostate carcinoma cells. Br J Cancer 2001;85:735-40.
21. Terry S, Ploussard G, Allory Y, et al. Increased expression of class III β-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009;101:951-6.
22. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
23. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
24. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
25. Azoulay S, Terry S, Chimingqi M, et al. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol 2008;216:460-70.
26. Frigo DE, McDonnell DP. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 2008;7:659-69.
27. Ranganathan S, Salazar H, Benetatos CA, Hudes GR. Immunohistochemical analysis of β-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate 1997;30:263-8.
28. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
29. Sramkoski RM, Pretlow TG II, Giaconia JM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-9.
30. Mickey DD, Stone KR, Wunderli H, Mickey GH, Paulson DF. Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. Prog Clin Biol Res 1980;37:67-84.
31. Cindolo L, Cantile M, Vacherot F, Terry S, de la Taille A. Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int 2007;79:287-96.
32. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14:531-47.
33. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
34. Walz J, Chun FK, Klein EA, et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009;181:601-7; discussion 607-8.
35. Burkhart CA, Kavallaris M, Band Horwitz S. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:O1-9.
36. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999;80:1020-5.
37. Akasaka K, Maesawa C, Shibazaki M, et al. Loss of class III β-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J Invest Dermatol 2009;129:1516-26.
38. Kamath K, Wilson L, Cabral F, Jordan MA. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005;280:12902-7.
39. Seve P, Isaac S, Tredan O, et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-6.
40. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 1997;36:3554-62.
41. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003;56:45-56.
42. Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305.
43. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of βIII-tubulin. Mol Cancer Ther 2010;9:1339-48.
44. Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. Class III β-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 2010;102:316-24.
45. Gan PP, Pasquier E, Kavallaris M. Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67:9356-63.
46. Blade K, Menick DR, Cabral F. Overexpression of class I, II or IVb β-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J Cell Sci 1999;112:2213-21.
47. Gan PP, Kavallaris M. Tubulin-targeted drug action: functional significance of class ii and class IVb β-tubulin in vinca alkaloid sensitivity. Cancer Res 2008;68:9817-24.
48. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406.
49. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009;20:492-7.
50. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of β(III)- and β(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996;56:2584-9.